OAOmar Alkasabrah

Omar Alkasabrah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Omar Alkasabrah has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of bariatric surgery on cardiovascular and cerebrovascular outcomes in metabolic dysfunction–associated steatotic liver disease: a nationwide analysis

    by Omar Alkasabrah, Mohamed ElZayat, Muhammad Qasim Chaudhry, Mohamed H. Eldesouki, Sameeha Ibrahim, Abdullah Serhan, Tanuj Sharma

    Metabolic dysfunction–associated steatotic liver disease (MASLD), the recently adopted term replacing nonalcoholic fatty liver disease (NAFLD), has become the most prevalent chronic liver condition...

  • Early versus late direct endoscopic necrosectomy for pancreatic walled-off necrosis: a grade‑assessed systematic review with trial sequential evidence

    by Mostafa Adel T. Mahmoud, Islam Mohamed, Alshayma Alalawneh, EzzElDien A. Ibrahim, Omar Alkasabrah, Abdelrahman Awad, Mohamed Abuelazm, Mohamed Elnaggar, Ismail Elkhattib

  • Comparative Effectiveness of Upadacitinib Versus Ustekinumab in Ulcerative Colitis Patients With Prior Tumor Necrosis Factor Inhibitor Exposure

    by Mohamed H. Eldesouki, Khaled Elfert, Omar Alkasabrah, Muhammad M. Elsharkawy, Mohamed Elzayat, Mohamed Mouhand, Kanwarpreet Tandon, Jennifer Hadam-Veverka, Mouhand Mahmoud

    Background and Aims: Upadacitinib, a selective janus kinase 1 (JAK1) inhibitor, and ustekinumab, an interleukin-12/23 inhibitor, are approved for the treatment of moderate-to-severe ulcerative colitis (UC). However, real-world data in patients with anti-tumor necrosis factor (TNF)-exposure are limited. Methods: We performed a retrospective cohort study in TriNetX US Collaborative Network. Adult patients with UC and prior anti-TNF exposure were identified. Patients who received upadacitinib or ustekinumab between April 2022 and August 2024 were stratified into two cohorts. Patients with Crohn’s disease, rheumatoid arthritis, psoriasis and ankylosing spondylitis were excluded. Propensity-score matching was performed to balance comorbidities, medications, and labs between the two cohorts. Study outcomes included rates of corticosteroid use, colectomies, change of therapy, hospital admissions or emergency department visit, and all-cause mortality. Results: A total of 724 patients in the upadacitinib cohort and 909 in the ustekinumab cohort met the inclusion criteria. After matching, 633 patients remained in each cohort, with balanced baseline characteristics. At 1-year follow-up, the rates of corticosteroid use were 40.1% in the upadacitinib group and 48.5% in the ustekinumab group (aOR= 0.71, 95% CI: 0.69-0.89), mainly driven by differences in oral corticosteroid use (aOR= 0.73, 95% CI: 0.58-0.91). All other outcomes were comparable between the two study groups. Conclusion: In patients with ulcerative colitis and prior anti-TNF exposure, upadacitinib was associated with lower oral corticosteroid use than ustekinumab over 1 year, with no significant differences in rates of colectomy, ED visits or hospitalizations. These findings suggest a potanial higher effectiveness of upadacitinib compared with ustekinumab and may help inform treatment selection in this population.


  • Open Access

    Twenty-Five Years of Angina–Related Mortality in Elderly Adults Aged ≥ 65 Years: A Retrospective Cohort Study Using Real-World Data from the USA

    by Mohamed Fawzi Hemida, Alyaa Ahmed Ibrahim, Anika Goel, Mirna Hussein, Krish Patel, Muhammad Raza Sarfraz, Omar Y. Alkasabrah, Maryam Saghir, Komal Karmani, Eshal Saghir, et al.

    Introduction: Angina is one of the ischemic heart diseases (IHD) that contributes to major cardiovascular complications up to death. We aim to assess angina-related mortality among adults aged ≥65 years in the U.S. Methods: Nationwide mortality records were obtained from the CDC-WONDER database from 1999 to 2023 among U.S. adults aged ≥65 with angina. Age-adjusted mortality rates (AAMRs) were calculated per 100,000 population. Joinpoint regression analysis was utilized to evaluate average annual percent changes (AAPCs). Results: From 1999 to 2023, a total of 36,544 deaths occurred among the elderly with angina in the U.S. The overall AAMR per 100,000 decreased from 7.52 in 1999 to 3.73 in 2023 (AAPC of -3.18; 95%CI: -3.79 to -2.75; p < 0.001). The AAMR for men decreased from 8.22 in 1999 to 4.75 in 2023 (AAPC of -2.53%; 95%CI: -3.02 to -2.09), and for women decreased from 6.95 in 1999 to 3.02 in 2023 (AAPC: -3.55%; 95%CI: -4.12 to -3.09). Across racial/ethnic groups, the highest overall rates were observed among NH-White individuals, 3.56. Overall, AAMRs were highest in the West, 4.00. The majority of deaths occurred in medical facilities (40.19%). Between 1999 and 2020, rural areas had a higher overall AAMR of 4.37 compared to urban areas, which had a rate of 3.02. Conclusion: Trends in angina-related mortality declined from 1999 to 2023. Higher mortality rates were observed in men, rural areas, the West region, and among NH White individuals. Our findings indicated that these categories require targeted interventions to reduce mortality.